BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 34071408)

  • 1. Atovaquone Suppresses the Growth of Metastatic Triple-Negative Breast Tumors in Lungs and Brain by Inhibiting Integrin/FAK Signaling Axis.
    Gupta N; Srivastava SK
    Pharmaceuticals (Basel); 2021 May; 14(6):. PubMed ID: 34071408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Penfluridol: An Antipsychotic Agent Suppresses Metastatic Tumor Growth in Triple-Negative Breast Cancer by Inhibiting Integrin Signaling Axis.
    Ranjan A; Gupta P; Srivastava SK
    Cancer Res; 2016 Feb; 76(4):877-90. PubMed ID: 26627008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atovaquone: An Antiprotozoal Drug Suppresses Primary and Resistant Breast Tumor Growth by Inhibiting HER2/β-Catenin Signaling.
    Gupta N; Srivastava SK
    Mol Cancer Ther; 2019 Oct; 18(10):1708-1720. PubMed ID: 31270151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atovaquone Suppresses Triple-Negative Breast Tumor Growth by Reducing Immune-Suppressive Cells.
    Gupta N; Gaikwad S; Kaushik I; Wright SE; Markiewski MM; Srivastava SK
    Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34068008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overexpression of the miR-141/200c cluster promotes the migratory and invasive ability of triple-negative breast cancer cells through the activation of the FAK and PI3K/AKT signaling pathways by secreting VEGF-A.
    Choi SK; Kim HS; Jin T; Hwang EH; Jung M; Moon WK
    BMC Cancer; 2016 Aug; 16():570. PubMed ID: 27484639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ziyuglycoside II suppresses the aggressive phenotype of triple negative breast cancer cells through regulating Src/EGFR-dependent ITGB4/FAK signaling.
    Wang K; Zou P; Zhu X; Zhang T
    Toxicol In Vitro; 2019 Dec; 61():104653. PubMed ID: 31525383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cucurbitacin B inhibits breast cancer metastasis and angiogenesis through VEGF-mediated suppression of FAK/MMP-9 signaling axis.
    Sinha S; Khan S; Shukla S; Lakra AD; Kumar S; Das G; Maurya R; Meeran SM
    Int J Biochem Cell Biol; 2016 Aug; 77(Pt A):41-56. PubMed ID: 27210504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An EGFR/Src-dependent β4 integrin/FAK complex contributes to malignancy of breast cancer.
    Tai YL; Chu PY; Lai IR; Wang MY; Tseng HY; Guan JL; Liou JY; Shen TL
    Sci Rep; 2015 Nov; 5():16408. PubMed ID: 26549523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrin α5 down-regulation by miR-205 suppresses triple negative breast cancer stemness and metastasis by inhibiting the Src/Vav2/Rac1 pathway.
    Xiao Y; Li Y; Tao H; Humphries B; Li A; Jiang Y; Yang C; Luo R; Wang Z
    Cancer Lett; 2018 Oct; 433():199-209. PubMed ID: 29964204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 3,4-Methylenedioxy-β-nitrostyrene inhibits adhesion and migration of human triple-negative breast cancer cells by suppressing β1 integrin function and surface protein disulfide isomerase.
    Chen IH; Chang FR; Wu YC; Kung PH; Wu CC
    Biochimie; 2015 Mar; 110():81-92. PubMed ID: 25593085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Focal adhesion kinase (FAK) activation by estrogens involves GPER in triple-negative breast cancer cells.
    Rigiracciolo DC; Santolla MF; Lappano R; Vivacqua A; Cirillo F; Galli GR; Talia M; Muglia L; Pellegrino M; Nohata N; Di Martino MT; Maggiolini M
    J Exp Clin Cancer Res; 2019 Feb; 38(1):58. PubMed ID: 30728047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Luteolin inhibits lung metastasis, cell migration, and viability of triple-negative breast cancer cells.
    Cook MT; Liang Y; Besch-Williford C; Hyder SM
    Breast Cancer (Dove Med Press); 2017; 9():9-19. PubMed ID: 28096694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p53 deficiency linked to B cell translocation gene 2 (BTG2) loss enhances metastatic potential by promoting tumor growth in primary and metastatic sites in patient-derived xenograft (PDX) models of triple-negative breast cancer.
    Powell E; Shao J; Yuan Y; Chen HC; Cai S; Echeverria GV; Mistry N; Decker KF; Schlosberg C; Do KA; Edwards JR; Liang H; Piwnica-Worms D; Piwnica-Worms H
    Breast Cancer Res; 2016 Jan; 18(1):13. PubMed ID: 26818199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pterostilbene inhibits triple-negative breast cancer metastasis via inducing microRNA-205 expression and negatively modulates epithelial-to-mesenchymal transition.
    Su CM; Lee WH; Wu AT; Lin YK; Wang LS; Wu CH; Yeh CT
    J Nutr Biochem; 2015 Jun; 26(6):675-85. PubMed ID: 25792283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Involvement of actin cytoskeletal modifications in the inhibition of triple-negative breast cancer growth and metastasis by nimbolide.
    Arumugam A; Subramani R; Lakshmanaswamy R
    Mol Ther Oncolytics; 2021 Mar; 20():596-606. PubMed ID: 33768141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting LC3 and Beclin-1 autophagy genes suppresses proliferation, survival, migration and invasion by inhibition of Cyclin-D1 and uPAR/Integrin β1/ Src signaling in triple negative breast cancer cells.
    Hamurcu Z; Delibaşı N; Geçene S; Şener EF; Dönmez-Altuntaş H; Özkul Y; Canatan H; Ozpolat B
    J Cancer Res Clin Oncol; 2018 Mar; 144(3):415-430. PubMed ID: 29288363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FAK activation is required for IGF1R-mediated regulation of EMT, migration, and invasion in mesenchymal triple negative breast cancer cells.
    Taliaferro-Smith L; Oberlick E; Liu T; McGlothen T; Alcaide T; Tobin R; Donnelly S; Commander R; Kline E; Nagaraju GP; Havel L; Marcus A; Nahta R; O'Regan R
    Oncotarget; 2015 Mar; 6(7):4757-72. PubMed ID: 25749031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral delivery of PND-1186 FAK inhibitor decreases tumor growth and spontaneous breast to lung metastasis in pre-clinical models.
    Walsh C; Tanjoni I; Uryu S; Tomar A; Nam JO; Luo H; Phillips A; Patel N; Kwok C; McMahon G; Stupack DG; Schlaepfer DD
    Cancer Biol Ther; 2010 May; 9(10):778-90. PubMed ID: 20234193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In Vivo Selection of Intermediately- and Highly-Malignant Variants of Triple-negative Breast Cancer in Orthotopic Nude Mouse Models.
    Yano S; Takehara K; Kishimoto H; Tazawa H; Urata Y; Kagawa S; Bouvet M; Fujiwara T; Hoffman RM
    Anticancer Res; 2016 Dec; 36(12):6273-6277. PubMed ID: 27919946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FOXM1 transcriptionally regulates expression of integrin β1 in triple-negative breast cancer.
    Hamurcu Z; Kahraman N; Ashour A; Ozpolat B
    Breast Cancer Res Treat; 2017 Jun; 163(3):485-493. PubMed ID: 28361350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.